Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US FDA updates Sanofi’s Dupixent label for atopic dermatitis
The trial’s primary endpoint was the proportion of patients achieving clear or almost clear skin on hands and feet at 16 weeks. Credit: (El Caminante) from Pixabay.
The trial’s primary endpoint was the proportion of patients achieving clear or almost clear skin on hands and feet at 16 weeks. Credit: (El Caminante) from Pixabay.